Pioneering Soft-Matter
Bio-Barrier Technologies

Birmingham Biotech and Birmingham Biomat unite academic
excellence with commercial execution to deliver scientifically led
healthcare innovations designed for global impact.

Pioneering Soft-Matter Bio-Barrier
Technologies

Birmingham Biotech and Birmingham Biomat unite academic excellence with commercial execution to deliver scientifically led healthcare innovations designed for global impact.

Shop Now

See It In Action

Innovation to Impact

Birmingham Biotech and its sister company Birmingham Biomat form a UK-based group focused on soft-matter bio-barrier technologies and practical medical devices for everyday life. Birmingham Biomat leads R&D and platform development. Birmingham Biomat (BBio) is the R&D and technology engine behind the Birmingham Biotech group.

Birmingham Biotech leads commercialisation, market access and global distribution. NoriZite^® products are available in the UK and selected international markets via distribution partners.

Birmingham Biotech

Rooted in University of Birmingham innovation, Birmingham Biotech is redefining respiratory defense. Our mission is to provide a powerful invisible shield, giving you the confidence to breathe freely anywhere.

Title

View Science & Platform

Birmingham Biomat

Birmingham Biotech is at the forefront of mucosal immunology and structural bio-engineering. Our mission is to empower healthcare professionals that provide patients with a reliable first line of defense in high-risk environments.

Title

View Science & Platform

Our Team

Combines world-class biomaterials science, product and process engineering, and global commercial execution.

Founder & CEO

Michael Hsu

Technology and life-sciences entrepreneur with over 15 years’ experience building and scaling innovation-driven companies, specialising in taking IP from lab to launch, cross-border business development and introducing new biomaterial-based products into global healthcare systems.

Co-founder & Chief Scientist

Prof. Liam Grover, FMedSci

Professor of Biomaterials Science and Head of the School of Chemical Engineering at the University of Birmingham, and the founding Director of the Healthcare Technologies Institute. He is a world-leading biomaterials innovator and co-inventor of the elastic-templated bio-barrier technology, with over 30 patent filings, five products taken from concept to first-in-human trials (including two now available internationally) and more than £50 million in competitively awarded research funding, including a UK government-backed Innovation Accelerator in Medical Technology.

Co-founder & Head of Formulation

Dr Richard Moakes

Associate Professor in Healthcare Materials and a co-inventor of the nasal spray technology, specialising in soft-materials formulation and mucosal delivery; he has taken multiple new therapies into clinical trials and one technology all the way to market.

Chief Technology Officer

Dr Julie Tzu-Wen Wang

A pharmaceutical scientist by training, with a PhD in photobiology in cancer therapeutics and more than a decade of research experience in drug delivery and translational nanomedicine at leading UK universities, she leads BHM’s technology and process development, working with universities, research institutes and manufacturing partners to translate biomaterial innovations into robust, scalable and manufacturable products that meet real-world clinical and consumer needs.

Our Team

Combines world-class biomaterials science, product and process engineering, and global commercial execution.

Founder & CEO

Michael Hsu

Technology and life-sciences entrepreneur with over 15 years’ experience building and scaling innovation-driven companies, specialising in taking IP from lab to launch, cross-border business development and introducing new biomaterial-based products into global healthcare systems.

Co-founder & Chief Scientist

Prof. Liam Grover, FMedSci

Professor of Biomaterials Science and Head of the School of Chemical Engineering at the University of Birmingham, and the founding Director of the Healthcare Technologies Institute. He is a world-leading biomaterials innovator and co-inventor of the elastic-templated bio-barrier technology, with over 30 patent filings, five products taken from concept to first-in-human trials (including two now available internationally) and more than £50 million in competitively awarded research funding, including a UK government-backed Innovation Accelerator in Medical Technology.

Co-founder & Head of Formulation

Dr Richard Moakes

Associate Professor in Healthcare Materials and a co-inventor of the nasal spray technology, specialising in soft-materials formulation and mucosal delivery; he has taken multiple new therapies into clinical trials and one technology all the way to market.

Chief Technology Officer

Dr Julie Tzu-Wen Wang

A pharmaceutical scientist by training, with a PhD in photobiology in cancer therapeutics and more than a decade of research experience in drug delivery and translational nanomedicine at leading UK universities, she leads BHM’s technology and process development, working with universities, research institutes and manufacturing partners to translate biomaterial innovations into robust, scalable and manufacturable products that meet real-world clinical and consumer needs.

Inside The Lab

Our Team

Combines world-class biomaterials science, product and process engineering, and global commercial execution.

Founder & CEO

Michael Hsu

Technology and life-sciences entrepreneur with over 15 years’ experience building and scaling innovation-driven companies, specialising in taking IP from lab to launch, cross-border business development and introducing new biomaterial-based products into global healthcare systems.

Co-founder & Head of Formulation

Dr Richard Moakes

Associate Professor in Healthcare Materials and a co-inventor of the nasal spray technology, specialising in soft-materials formulation and mucosal delivery; he has taken multiple new therapies into clinical trials and one technology all the way to market.

Co-founder & Chief Scientist

Prof. Liam Grover, FMedSci

Professor of Biomaterials Science and Head of the School of Chemical Engineering at the University of Birmingham, and the founding Director of the Healthcare Technologies Institute. He is a world-leading biomaterials innovator and co-inventor of the elastic-templated bio-barrier technology, with over 30 patent filings, five products taken from concept to first-in-human trials (including two now available internationally) and more than £50 million in competitively awarded research funding, including a UK government-backed Innovation Accelerator in Medical Technology.

Chief Technology Officer

Dr Julie Tzu-Wen Wang

A pharmaceutical scientist by training, with a PhD in photobiology in cancer therapeutics and more than a decade of research experience in drug delivery and translational nanomedicine at leading UK universities, she leads BHM’s technology and process development, working with universities, research institutes and manufacturing partners to translate biomaterial innovations into robust, scalable and manufacturable products that meet real-world clinical and consumer needs.